Novel Approaches to Enhancing Social Cognition by Stimulating Oxytocin Release
通过刺激催产素释放来增强社会认知的新方法
基本信息
- 批准号:8837869
- 负责人:
- 金额:$ 4.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-10 至 2017-09-09
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAnimal ModelBehavior assessmentBehavioralBehavioral ParadigmBlood - brain barrier anatomyBrainClinical ResearchCognitiveComplexDataDevelopmentDopamineFaceFemaleFutureHumanHypothalamic structureIn VitroInfusion proceduresInjection of therapeutic agentInvestigationKnowledgeLearningMediatingMelanocortin 4 ReceptorMental disordersMicrotusModelingMolecular GeneticsNeuronsOpiatesOxytocinOxytocin ReceptorPartner in relationshipPatientsPeripheralPersonsPharmacologic SubstancePlayProcessProsencephalonPsychological reinforcementQuality of lifeRattusReceptor ActivationRegulationRewardsRodent ModelRoleRouteSchizophreniaSignal TransductionSiteSocial BehaviorSocial DevelopmentSocial FunctioningSocial ReinforcementSourceStudy modelsSystemTestingTherapeuticTreatment EfficacyViral Vectorautism spectrum disorderbehavior testcell typeclinical applicationgenetic manipulationimprovedinformation processinginnovationinsightknock-downmalemelanotan-IIneurobiological mechanismneurotransmissionnovelnovel strategiesparaventricular nucleuspatient populationprairie volepreferencepreventpromoterpublic health relevancereceptor expressionresearch studyscreeningsmall hairpin RNAsocialsocial attachmentsocial cognition
项目摘要
DESCRIPTION (provided by applicant): Oxytocin (OT) plays a role in mammalian social behavior in both model animals and humans. The ability of OT to broadly enhance social cognition makes it a viable candidate for improving social function in psychiatric disorders characterized by social deficits, including Autism Spectrum Disorder. Indeed, intranasal OT has been shown to enhance some facets of social cognition in both healthy and patient populations. Unfortunately, the extent to which intranasal OT penetrates the blood-brain barrier to broadly activate central OT receptors is likely a limiting factor in the efficacy of this therapeutic approach. Melanocortin agonists are proposed as an alternative approach to stimulate central release of OT to enhance social cognition. Melanocortin agonists, acting at the brain-specific melanocortin 4 receptor (MC4R), have been previously shown to stimulate OT release in vitro. The socially monogamous prairie vole (Microtus ochrogaster) is a well-known model for the study of social cognition and social attachment. Formation of a partner preference in the prairie vole is a complex social cognitive process involving social information processing and social reinforcement that is facilitated by OT. We have recently shown that peripheral administration of Melanotan II (MTII), a compound with high selectivity for activating MC4R, enhances partner preference formation in male and female prairie voles. What remains unknown is the precise central mechanism by which MTII enhances partner preference formation, a knowledge gap that prevents accurate assessment of the potential clinical applicability of this approach. The overarching hypothesis of this proposal is that activation of MC4Rs located in the primary source of forebrain OT, the paraventricular nucleus of the hypothalamus, stimulates the OT system to enhance social cognition in the prairie vole. In Aim 1, we will determine whether MTII acts centrally at MC4R to facilitate partner preference formation using pharmacological manipulations combined with behavioral assessments. In Aim 2, we will determine the role of MC4R activation in the paraventricular nucleus of the hypothalamus, and the specific contribution of the OT system, in the behavioral effects of MTII. Aim 2 will use both pharmacological and molecular genetic manipulations in combination with behavioral assessment. The proposed experiments will advance our knowledge of functional social cognition as well as facilitate a greater understanding of how the OT system can potentially be manipulated therapeutically. This is a unique route of investigation in the search for novel treatments of social deficits in human psychiatric disorders.
描述(申请人提供):催产素(OT)在模式动物和人类的哺乳动物社会行为中发挥作用。OT广泛增强社会认知的能力使其成为改善以社会缺陷为特征的精神障碍(包括自闭症谱系障碍)的社会功能的可行候选者。事实上,鼻腔催产素已被证明在健康人群和患者群体中都能增强社会认知的某些方面。不幸的是,鼻腔OT穿透血脑屏障以广泛激活中枢OT受体的程度可能是该治疗方法疗效的限制因素。黑素皮质素激动剂被认为是刺激催产素中枢释放以增强社会认知的一种替代方法。黑素皮质素激动剂作用于大脑特定的黑素皮质素4受体(MC4R),已被证明在体外可以刺激OT的释放。社会一夫一妻制草原田鼠(Microtus Ochrogaster)是研究社会认知和社会依恋的著名模型。草原田鼠伴侣偏好的形成是一个复杂的社会认知过程,涉及社会信息加工和社会强化,这是由OT促进的。我们最近已经证明,外周给药黑素二号(MTII),一种具有高选择性激活MC4R的化合物,可以增强雄性和雌性草原田鼠的伴侣偏好形成。目前尚不清楚MTII增强伴侣偏好形成的确切核心机制,这是一个知识缺口,阻碍了对该方法潜在临床适用性的准确评估。这一假设的主要假设是,位于前脑OT的初级来源,即下丘脑室旁核的MC4Rs的激活,刺激OT系统来增强草原田鼠的社会认知。在目标1中,我们将确定MTII是否在MC4R发挥中央作用,通过结合药理学操作和行为评估来促进伴侣偏好的形成。在目标2中,我们将确定下丘脑室旁核MC4R激活的作用,以及OT系统在MTII行为效应中的具体贡献。AIM 2将同时使用药理学和分子遗传操作,并结合行为评估。拟议的实验将促进我们对功能性社会认知的了解,并有助于更好地理解OT系统如何潜在地被操纵为治疗性的。这是寻找人类精神疾病社会缺陷的新疗法的一条独特的调查路线。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kara Ann Kittelberger其他文献
Kara Ann Kittelberger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kara Ann Kittelberger', 18)}}的其他基金
Novel Approaches to Enhancing Social Cognition by Stimulating Oxytocin Release
通过刺激催产素释放来增强社会认知的新方法
- 批准号:
8929025 - 财政年份:2014
- 资助金额:
$ 4.27万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 4.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 4.27万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)